<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01885559</url>
  </required_header>
  <id_info>
    <org_study_id>DK62401-PKD-TN (IND)</org_study_id>
    <nct_id>NCT01885559</nct_id>
    <nct_alias>NCT00067977</nct_alias>
  </id_info>
  <brief_title>HALT Progression of Polycystic Kidney Disease (HALT PKD) Study B</brief_title>
  <acronym>HALT-PKD</acronym>
  <official_title>Polycystic Kidney Disease-Treatment Network</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Polycystic Kidney Disease Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The efficacy of interruption of the renin-angiotensin-aldosterone system (RAAS) on the
      progression of cystic disease and on the decline in renal function in autosomal dominant
      kidney disease (ADPKD) will be assessed in two simultaneous multicenter randomized clinical
      trials targeting different levels of kidney function: 1) early disease defined by GFR &gt;60
      mL/min/1.73 m2 (Study A); and 2) moderately advanced disease defined by GFR 25-60 mL/min/1.73
      m2 (Study B). Participants will be recruited and enrolled, either to Study A or B, over the
      first three years. Participants enrolled in Study B will be followed for five-to-eight years,
      with the average length of follow-up being six and a half years.

      Combination therapy will use angiotensin-converting-enzyme inhibitor (ACE-I) and an
      angiotensin-receptor blocker (ARB). Monotherapy will use ACE-I alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      * Specific Aim of Study B

      To study the effects of ACE-I/ARB combination therapy as compared to ACE-I monotherapy in the
      setting of standard blood pressure control (110-130/80 mm Hg) on the time to a 50% reduction
      of baseline estimated Glomerular Filtration Rate (eGFR), end-state renal disease (ESRD) or
      death, in hypertensive individuals with moderate renal insufficiency (GFR 25-60
      mL/min/1.73m2).

      * Hypothesis to be tested in Study B

      In hypertensive ADPKD individuals with moderate renal insufficiency (GFR 25-60 mL/min/1.73
      m2), intensive blockade of the RAAS using combination ACE-I/ARB therapy will slow the decline
      in kidney function over ACE-I monotherapy, independent of standard blood pressure control
      (110-130/80 mm Hg).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">June 2014</completion_date>
  <primary_completion_date type="Actual">June 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.</measure>
    <time_frame>Patients followed for 5-8 years with average of 6.5 years follow up</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Albuminuria</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <description>Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Aldosterone</measure>
    <time_frame>up at 8 years (annually assessed)</time_frame>
    <description>Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalizations</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Hospitalization for any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular Hospitalizations</measure>
    <time_frame>up to 8 years</time_frame>
    <description>Cause-specific hospitalizations (cardiovascular)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Physical Component Summary</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Mental Component Summary</measure>
    <time_frame>up to 8 years (annually assessed)</time_frame>
    <description>Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>48 months</time_frame>
    <description>Kidney pain (back or flank pain) experienced in since last visit</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">486</enrollment>
  <condition>Kidney, Polycystic</condition>
  <arm_group>
    <arm_group_label>ACE-I + placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Monotherapy of lisinopril and placebo. Standard blood pressure control of 110-130/80 mm Hg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ACE-I + ARB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dual therapy of lisinopril and telmisartan treatments. Standard blood pressure control of 110-130/80 mm Hg.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lisinopril</intervention_name>
    <description>Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
    <arm_group_label>ACE-I + placebo</arm_group_label>
    <arm_group_label>ACE-I + ARB</arm_group_label>
    <other_name>ACE-I</other_name>
    <other_name>ACE</other_name>
    <other_name>Ace-Inhibitor</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Telmisartan</intervention_name>
    <description>Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
    <arm_group_label>ACE-I + ARB</arm_group_label>
    <other_name>ARB</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
    <arm_group_label>ACE-I + placebo</arm_group_label>
    <other_name>Control</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of ADPKD.

          -  Age 15-49 (Study A); Age 18-64 (Study B).

          -  GFR &gt;60 mL/min/1.73 m2 (Study A); GFR 25-60 mL/min/1.73 m2 (Study B).

          -  BP ≥130/80 or receiving treatment for hypertension.

          -  Informed Consent.

        Exclusion Criteria:

          -  Pregnant/intention to become pregnant in 4-6 yrs.

          -  Documented renal vascular disease.

          -  Spot urine albumin-to-creatinine ratio of &gt;0.5 (Study A) or ≥1.0 (Study B) and/or
             findings suggestive of kidney disease other than ADPKD.

          -  Diabetes requiring insulin or oral hypoglycemic agents / fasting serum glucose of &gt;126
             mg/dl / random non-fasting glucose of &gt;200 mg/dl.

          -  Serum potassium &gt;5.5 milliequivalent (mEq) /L for participants currently on ACE-I or
             ARB; &gt;5.0 mEq/L for participants not currently on ACE-I or ARB.

          -  History of angioneurotic edema or other absolute contraindication for ACE-I or ARB.
             Intolerable cough associated with ACE-I is defined as a cough developing within six
             months of initiation of ACE-I in the absence of other causes and resolving upon
             discontinuation of the ACE-I.

          -  Indication (other than hypertension) for β-blocker or calcium channel blocker therapy
             (e.g. angina, past myocardial infarction, arrhythmia), unless approved by the site
             principal investigator. (PI may choose to accept an individual who is on only a small
             dose of one of these agents and would otherwise be eligible.)

          -  Systemic illness necessitating nonsteroidal antiinflammatory drugs (NSAIDs),
             immunosuppressant or immunomodulatory medications.

          -  Systemic illness with renal involvement.

          -  Hospitalized for acute illness in past 2 months.

          -  Life expectancy &lt;2 years.

          -  History of non-compliance.

          -  Unclipped cerebral aneurysm &gt;7mm diameter.

          -  Creatine supplements within 3 months of screening visit.

          -  Congenital absence of a kidney (also total nephrectomy for Study B).

          -  Known allergy to sorbitol or sodium polystyrene sulfonate.

          -  Exclusions specific to magnetic resonance (MR) imaging (Study A).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Schrier, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Arlene Chapman, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ronald Perrone, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tufts University-New England Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Vicente Torres, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marva Moxey-Mims, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Charity G Moore, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Health Sciences Center</name>
      <address>
        <city>Denver (Aurora)</city>
        <state>Colorado</state>
        <zip>800045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Emory University School of Medicine</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Medical Center</name>
      <address>
        <city>Kansas City</city>
        <state>Kansas</state>
        <zip>66160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University-New England Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beth Israel Deaconess Medical Center</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.pkdcure.org</url>
    <description>Polycystic Kidney Disease Foundation Website</description>
  </link>
  <link>
    <url>http://www.niddk.nih.gov/welcome/welcome.htm</url>
    <description>National Institute of Diabetes &amp; Digestive &amp; Kidney Diseases Website</description>
  </link>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 25, 2013</study_first_posted>
  <results_first_submitted>February 2, 2015</results_first_submitted>
  <results_first_submitted_qc>February 25, 2015</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 10, 2015</results_first_posted>
  <last_update_submitted>February 25, 2015</last_update_submitted>
  <last_update_submitted_qc>February 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 10, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Charity G Moore, PhD</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>polycystic kidney disease</keyword>
  <keyword>polycystic</keyword>
  <keyword>kidney</keyword>
  <keyword>disease</keyword>
  <keyword>adpkd</keyword>
  <keyword>halt</keyword>
  <keyword>pkd</keyword>
  <keyword>blood pressure</keyword>
  <keyword>bp</keyword>
  <keyword>hypertension</keyword>
  <keyword>renal</keyword>
  <keyword>renin-angiotensin-aldosterone-system</keyword>
  <keyword>RAAS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Polycystic Kidney Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Telmisartan</mesh_term>
    <mesh_term>Lisinopril</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment for HALT PKD Study B occurred at seven clinical sites between February 2006 and June 2009.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ACE-I + Placebo</title>
          <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
        <group group_id="P2">
          <title>ACE-I + Angiotensin Receptor Blocker (ARB)</title>
          <description>ACE-I + angiotensin receptor blocker (ARB) and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="242"/>
                <participants group_id="P2" count="244"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="218"/>
                <participants group_id="P2" count="208"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="36"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="16"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Less than full participation</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="19"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ACE-I + Placebo</title>
          <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
        <group group_id="B2">
          <title>ACE-I + ARB</title>
          <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="242"/>
            <count group_id="B2" value="244"/>
            <count group_id="B3" value="486"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.9" spread="8.1"/>
                    <measurement group_id="B2" value="48.6" spread="8.5"/>
                    <measurement group_id="B3" value="48.7" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="122"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="251"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="120"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="235"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="230"/>
                    <measurement group_id="B3" value="454"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>PKD Genotype</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>PKD1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="183"/>
                    <measurement group_id="B2" value="179"/>
                    <measurement group_id="B3" value="362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PKD2</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No Mutation Detected</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>No data</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age at Diagnosis of Autosomal Dominant Polycystic Kidney Disease (yrs)</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.5" spread="12.4"/>
                    <measurement group_id="B2" value="33.0" spread="12.0"/>
                    <measurement group_id="B3" value="33.2" spread="12.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (kg/m2)</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="5.5"/>
                    <measurement group_id="B2" value="28.0" spread="4.9"/>
                    <measurement group_id="B3" value="28.0" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Serum Creatinine (mg/dl)</title>
          <units>mg/dl</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.6" spread="0.4"/>
                    <measurement group_id="B2" value="1.5" spread="0.4"/>
                    <measurement group_id="B3" value="1.6" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Chronic Kidney Disease Epidemiology Collaboration (CKD EPI) eGFR (ml/min/m^2)</title>
          <units>ml/min/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="12.2"/>
                    <measurement group_id="B2" value="48.5" spread="11.5"/>
                    <measurement group_id="B3" value="48.2" spread="11.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.</title>
        <time_frame>Patients followed for 5-8 years with average of 6.5 years follow up</time_frame>
        <population>Intention to Treat analysis was used for the primary outcome</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 50% Reduction of Baseline eGFR, End Stage Renal Disease (ESRD, Initiation of Dialysis or Preemptive Transplant), or Death.</title>
          <population>Intention to Treat analysis was used for the primary outcome</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="115"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.58</p_value>
            <method>Regression, Cox</method>
            <method_desc>Analyses were adjusted for age, sex, race, baseline estimated Glomerular Filtration Rate (eGFR) and clinical site</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
            <estimate_desc>ACE+ARB (Lisinopril-telmisartan) compared to ACE+placebo (Lisinopril-placebo)</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Albuminuria</title>
        <description>Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years.</description>
        <time_frame>up to 8 years (annually assessed)</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Albuminuria</title>
          <description>Annual percent change in 24 hour urine albumin, centrally processed. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope of the model). The measure presented is the average annual percent change across the 8 years.</description>
          <population>Intention to treat analysis</population>
          <units>annual percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.5" lower_limit="5.2" upper_limit="9.9"/>
                    <measurement group_id="O2" value="7.3" lower_limit="4.9" upper_limit="9.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.88</p_value>
            <method>shared parameter model</method>
            <method_desc>shared parameter models used due to informative censoring that occurred when patients did not have secondary outcomes measured after reaching endpoint</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>2.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Aldosterone</title>
        <description>Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years.</description>
        <time_frame>up at 8 years (annually assessed)</time_frame>
        <population>Intention to treat analyses</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Aldosterone</title>
          <description>Annual percent change in urinary aldosterone, centrally processed measure. Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual percent change across the 8 years.</description>
          <population>Intention to treat analyses</population>
          <units>annual percent change</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.8" lower_limit="-10.5" upper_limit="-7.2"/>
                    <measurement group_id="O2" value="-10.2" lower_limit="-11.9" upper_limit="-8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <p_value_desc>controlling for age, sex, race, and clinical site</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.9</ci_lower_limit>
            <ci_upper_limit>0.7</ci_upper_limit>
            <estimate_desc>ACE-I+ARB annual percent change minus ACE-I + placebo annual percent change</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospitalizations</title>
        <description>Hospitalization for any cause</description>
        <time_frame>up to 8 years</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospitalizations</title>
          <description>Hospitalization for any cause</description>
          <population>Intention to treat analysis</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="173"/>
                    <measurement group_id="O2" value="136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>Regression, Cox</method>
            <method_desc>adjusting for age, sex, race, and clinical site and recurrent events</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>Hazard ratio compares ACE-I + ARB compared to ACE-I + placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cardiovascular Hospitalizations</title>
        <description>Cause-specific hospitalizations (cardiovascular)</description>
        <time_frame>up to 8 years</time_frame>
        <population>Intention to Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Cardiovascular Hospitalizations</title>
          <description>Cause-specific hospitalizations (cardiovascular)</description>
          <population>Intention to Treat analysis</population>
          <units>events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <method>Regression, Cox</method>
            <method_desc>adjusting for age, sex, race, and clinical site and accounting for recurrent events</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.42</ci_lower_limit>
            <ci_upper_limit>1.6</ci_upper_limit>
            <estimate_desc>Hazard ratio is comparing ACE-I + ARB to ACE-I + placebo</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Physical Component Summary</title>
        <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
        <time_frame>up to 8 years (annually assessed)</time_frame>
        <population>Intention to Treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Physical Component Summary</title>
          <description>Short Form-36 Quality of Life Physical Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
          <population>Intention to Treat analysis</population>
          <units>units on a scale per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.64" lower_limit="-0.79" upper_limit="-0.50"/>
                    <measurement group_id="O2" value="-0.68" lower_limit="-0.84" upper_limit="-0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <method>shared parameter model</method>
            <method_desc>Shared parameter models were used due to informed censoring when patients who reached the primary endpoint were no longer assessed on the measure.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.032</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Mental Component Summary</title>
        <description>Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
        <time_frame>up to 8 years (annually assessed)</time_frame>
        <population>Intention to treat analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Mental Component Summary</title>
          <description>Short Form-36 Quality of Life Mental Component Summary ranges from 0 (worst possible outcome) to 100 (best possible outcome). Data from multiple years were analyzed with the primary focus on the change over time for the measure (from the slope for time from the model). The measure presented is the average annual change across the 8 years.</description>
          <population>Intention to treat analysis</population>
          <units>units on a scale per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="242"/>
                <count group_id="O2" value="243"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.031" lower_limit="-0.19" upper_limit="0.12"/>
                    <measurement group_id="O2" value="-0.079" lower_limit="-0.24" upper_limit="0.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>shared parameter model</method>
            <method_desc>Shared parameter models were used due to the informative censoring when patients who reached endpoint were not longer assessed on this measure.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-0.047</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pain</title>
        <description>Kidney pain (back or flank pain) experienced in since last visit</description>
        <time_frame>48 months</time_frame>
        <population>Cross sectional analysis at 48 months is reported only for those participants responding at that time point. Intention to treat analysis was used for in the modeling over time to incorporate all repeated measures.</population>
        <group_list>
          <group group_id="O1">
            <title>ACE-I + Placebo</title>
            <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
          <group group_id="O2">
            <title>ACE-I + ARB</title>
            <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
          </group>
        </group_list>
        <measure>
          <title>Pain</title>
          <description>Kidney pain (back or flank pain) experienced in since last visit</description>
          <population>Cross sectional analysis at 48 months is reported only for those participants responding at that time point. Intention to treat analysis was used for in the modeling over time to incorporate all repeated measures.</population>
          <units>percentage of participants at 48 months</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="184"/>
                <count group_id="O2" value="179"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43" lower_limit="36" upper_limit="50"/>
                    <measurement group_id="O2" value="46" lower_limit="39" upper_limit="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Generalized linear mixed models are used with a logit link. Model controlled for baseline age, sex, race, and clinical site.</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.99</ci_lower_limit>
            <ci_upper_limit>1.01</ci_upper_limit>
            <estimate_desc>Odds ratio represents the multiplicative effect of ACE-I + ARB group compared to the ACE-I + placebo group in change in pain over time.
ACE-I + ARB OR per month was 1.01 (1.00, 1.01) and ACE-I + placebo OR was 1.01 (1.01, 1.01).</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse event data were collected during follow up between 5-8 years with average follow up time of 5.2 years.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>ACE-I + Placebo</title>
          <description>ACE-I + placebo and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Placebo: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
        <group group_id="E2">
          <title>ACE-I + ARB</title>
          <description>ACE-I + ARB and standard blood pressure control of 110-130/80 mm Hg
Lisinopril and Telmisartan: Lisinopril titrated to 5mg, 10mg, 20mg, 40mg and telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="88" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Blood and lymphatic system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Cardiac disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chest pain - cardiac</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Paroxysmal atrial tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute coronary syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mitral valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Aortic valve disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Endocrine disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="242"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Colonic obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Esophageal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Esophageal varices hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Esophagitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Rectal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death NOS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Flu like symptoms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>General disorders and administration site conditions - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Sudden death NOS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Edema limbs</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatic failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hepatobiliary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Anaphylaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Infections and infestations - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injury, poisoning and procedural complications - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Injury to carotid artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Spinal fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bladder anastomotic leak</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intraoperative renal injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Glucose intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Chest wall pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Musculoskeletal and connective tissue disorder - Other, specify</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Neoplasms benign, malignant and unspecified (incl cysts and polyps) - Other, specify</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="242"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Intracranial hemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Ischemia cerebrovascular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Nervous system disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Peripheral motor neuropathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Transient ischemic attacks</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy, puerperium and perinatal conditions - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal and urinary disorders - Other, specify</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="242"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal calculi</sub_title>
                <counts group_id="E1" events="5" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Renal hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary incontinence</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Reproductive system and breast disorders - Other, specify</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Uterine hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vaginal hemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pelvic floor muscle weakness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Adult respiratory distress syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Dyspnea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Respiratory, thoracic and mediastinal disorders - Other, specify</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Surgical and medical procedures - Other, specify</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="242"/>
                <counts group_id="E2" events="21" subjects_affected="15" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="242"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Thromboembolic event</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="242"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="244"/>
              </event>
              <event>
                <sub_title>Vascular disorders - Other, specify</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="242"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="242"/>
                <counts group_id="E2" subjects_affected="60" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="65" subjects_affected="41" subjects_at_risk="242"/>
                <counts group_id="E2" events="70" subjects_affected="46" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Kidney Injury</sub_title>
                <counts group_id="E1" events="51" subjects_affected="32" subjects_at_risk="242"/>
                <counts group_id="E2" events="31" subjects_affected="22" subjects_at_risk="244"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Vicente Torres</name_or_title>
      <organization>Mayo Clinic</organization>
      <email>torres.vicente@mayo.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

